@article{094246457de74cdd96868476796a9c9a,
title = "Five-year survival on infliximab in rheumatoid arthritis patients: analysis from an Italian registry (GISEA) by different calendar years",
abstract = "To assess long-term drug survival and effectiveness in biological drug-na{\"i}ve patients with rheumatoid arthritis (RA), starting infliximab as first treatment, in the period 2000-2009, comparing different calendar years.",
keywords = "Adult, Aged, Antibodies, Monoclonal, Antirheumatic Agents, Arthralgia, Arthritis, Rheumatoid, C-Reactive Protein, Demography, Disability Evaluation, Female, Humans, Infliximab, Italy, Kaplan-Meier Estimate, Male, Middle Aged, Pain Measurement, Patient Acuity, Patient Outcome Assessment, Registries, Remission Induction, Rheumatoid Factor, Time-to-Treatment, Adult, Aged, Antibodies, Monoclonal, Antirheumatic Agents, Arthralgia, Arthritis, Rheumatoid, C-Reactive Protein, Demography, Disability Evaluation, Female, Humans, Infliximab, Italy, Kaplan-Meier Estimate, Male, Middle Aged, Pain Measurement, Patient Acuity, Patient Outcome Assessment, Registries, Remission Induction, Rheumatoid Factor, Time-to-Treatment",
author = "Elisa Gremese",
year = "2015",
language = "English",
volume = "33",
pages = "524--530",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology:Via S Maria 31, I 56126 Pisa Italy:011 39 050 40124, EMAIL:
[email protected], INTERNET: http://www.clinexprhematol.org, Fax: 011 39 050 502299",
}